Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(1)
•••

Post by GJS471on Nov 09, 2022 8:59am

280 Views

Post# 35084738

Tomorrrow the wait will be over....

Given the recent increase in the stock price, people are obviously thinking that they will report a solid quarter but it also looks like an expectation of M&A activity. Which was what people were expecting last quarter. It would be interesting to see what they have been doing in stock purchases/retirement the last three months. Does anyone know what their stock purchases have been or where this information might be available?

<< Previous

Bullboard Posts

Next >>

Tungsten and molybdenum for the US military and Elon Musk: Why Almonty's NASDAQ listing could provide the next boost